Internal Reference Number: FOI_9286
Date Request Received: 13/03/2026 00:00:00
Date Request Replied To: 26/03/2026 00:00:00
This response was sent via: By Email
Request Summary: Oncology Gastro Cancer
Request Category: Companies
| Question Number 1: How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? | |
| Answer To Question 1: 14 patients | |
| Question Number 2: How many patients were treated in the past 3 months for gastric cancer (any stage) with: 鈥� CAPOX (Capecitabine with Oxaliplatin) 鈥� FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 鈥� Lonsurf (Trifluridine - tipiracil) 鈥� Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Zolbetuximab (Vyloy) 鈥� Any other systemic anti-cancer therapy 鈥� Palliative care only | |
| Answer To Question 2: 鈥� CAPOX (Capecitabine with Oxaliplatin) <=5 鈥� FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0 鈥� Lonsurf (Trifluridine - tipiracil) 0 鈥� Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 鈥� Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 鈥� Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 鈥� Zolbetuximab (Vyloy) 0 鈥� Any other systemic anti-cancer therapy 0 Palliative care only <=5 | |
| Question Number 3: How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: 鈥� CAPOX (Capecitabine with Oxaliplatin) 鈥� FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 鈥� Lonsurf (Trifluridine - tipiracil) 鈥� Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Zolbetuximab (Vyloy) 鈥� Any other systemic anti-cancer therapy 鈥� Palliative care only | |
| Answer To Question 3: 鈥� CAPOX (Capecitabine with Oxaliplatin) <=5 鈥� FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <=5 鈥� Lonsurf (Trifluridine - tipiracil) <=5 鈥� Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <=5 鈥� Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <=5 鈥� Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 鈥� Zolbetuximab (Vyloy) 0 鈥� Any other systemic anti-cancer therapy 9 Palliative Care only = 0 | |
| Question Number 4: If you have been unable to answer any of the above questions because you do not treat Gastric or Gastro-Oesophageal Cancer, to which site do you refer patients that require either treatment? | |
| Answer To Question 4: Not applicable | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
